Astal Laboratories Limited has intimated the BSE Limited about an upcoming meeting of its Board of Directors. The meeting is scheduled to be held on Saturday, 30th May, 2026 at the company's corporate office in Hyderabad, Telangana.
The agenda for the board meeting includes:
1. Consideration and approval of the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. This will include the limited review report from the auditors.
2. Consideration and approval of the audited standalone and consolidated financial statements of the Company for the financial year ended March 31, 2026, along with the report of the auditors.
3. Consideration for the appointment of an Internal Auditor for the Financial Year 2026-27.
4. Any other matter with the permission of the chair.
The disclosure is made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Furthermore, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct, the Trading Window for Designated Persons and their immediate relatives has been closed since April 01, 2026. The trading window will remain closed until forty-eight hours after the conclusion of the board meeting.
The letter is signed by Mahendra Kumar, Company Secretary & Compliance Officer (Membership No.: A71224), on behalf of Astal Laboratories Limited.